Kala Bio Inc (KALA)

$0.24 -0.01 (-3.70%)
Market Cap 230.11M
Revenue (ttm) 0.00
Net Income (ttm) -38.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -3.28
Volume 2,698,700
Avg Vol 7,728,246
Day's Range N/A - N/A
Shares Out 911.33M
Stochastic %K 5%
Beta -2.37
Analysts Strong Buy
Price Target $1.50

Company Profile

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The comp...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 996 5252
Fax: 781 642 0399
Address:
1167 Massachusetts Avenue, Arlington, United States
Atif98
Atif98 Mar. 21 at 6:01 PM
$KALA
0 · Reply
We_the_People_Fight
We_the_People_Fight Mar. 21 at 2:47 AM
$KALA So the AI news for 14-day window lands around: March 26, 2026 Now notice something important… March 26 = Earnings release day That is very interesting timing. Companies often: Release earnings Release PR/news same week Talk about partnership on earnings call Follow earnings with PR announcement This timing actually lines up very Logically: AI filing ~2 weeks later Earnings Earnings call Possible partnership/news
0 · Reply
JustDoItMF
JustDoItMF Mar. 21 at 12:22 AM
$KALA perfect attitude
0 · Reply
Wolfomw02
Wolfomw02 Mar. 20 at 11:03 PM
$KALA have a great weekend everybody! Do something fun get out of the house... Try to forget about the stock for now, come back with renewed interest. Because you all know news is coming next week. And we know what's going to be good because there's already been a buyer.. I guarantee there will be several more! Especially when they tell us what it actually does and how it performs on the 25th... Don't fret, we are either at the bottom or close to it. I'm used to the negative loss already I've been in this for quite a while. But I believe this is something special! and a sign of growth! Please be patient good things will come! But if you can't be patient, please get out and come back because we do need you!! I have 31,500 shares, scaled down from .44 to .32. I'm in it to win it! You should be too!
1 · Reply
We_the_People_Fight
We_the_People_Fight Mar. 20 at 10:27 PM
$KALA
0 · Reply
Momikhan
Momikhan Mar. 20 at 10:16 PM
$KALA so here is my summary for this stock at the moment. Positives AI Product Shipment Clearance of Partial Debt Working with other clients Oversold (Chance of Dead Cat bounce) High CTB Probably sold out to big company if product os good then it will go to Black swan or moon Shot event. Negatives Initial Drug or product failed Zero Revenue Nasdaq delisting notice tickling Continuous Decline with no active buyers Dilution Low cash. Important events 25th March for shipped product update 30th March Financial release (Investors will look cash burn details) My advice. Don't buy or sell at least till 30th of March yes you can average down but it's extreme risky, this is do and die stock. Invest on your own research. Thanks Goodnight !
1 · Reply
JustDoItMF
JustDoItMF Mar. 20 at 9:39 PM
$KALA for fun lets say you're right they would cancel it after the ridiculous pump and many wont even be here
0 · Reply
JustDoItMF
JustDoItMF Mar. 20 at 9:35 PM
$KALA Dont be so life and death the market was down and this company is sun in your eyes bright
1 · Reply
bilocelhi
bilocelhi Mar. 20 at 9:34 PM
$KALA RS within next three weeks. Mark it
0 · Reply
FinacialSuicide
FinacialSuicide Mar. 20 at 9:02 PM
$KALA very disappointing week! Holding next week as well! Hopefully that shipping news comes before the 25th. Let wait and see for now!
1 · Reply
Latest News on KALA
Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate

Mar 18, 2026, 9:00 AM EDT - 3 days ago

Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate

Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate

Mar 18, 2026, 8:15 AM EDT - 3 days ago

Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate

Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents

Mar 11, 2026, 11:18 AM EDT - 10 days ago

Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents

Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

Mar 11, 2026, 6:30 AM EDT - 10 days ago

Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

Stock Trend Capital Provides Younet AI Investment Update

Mar 9, 2026, 6:20 AM EDT - 12 days ago

Stock Trend Capital Provides Younet AI Investment Update

KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”

Mar 4, 2026, 6:30 AM EST - 17 days ago

KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”

KALA BIO Settles Approximately $10.6 million of Debt

Jan 5, 2026, 4:10 PM EST - 2 months ago

KALA BIO Settles Approximately $10.6 million of Debt

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Dec 4, 2025, 10:45 AM EST - 3 months ago

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday?

Sep 29, 2025, 12:00 PM EDT - 6 months ago

Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday?

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 8, 2025, 8:00 AM EDT - 8 months ago

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 6, 2025, 8:00 AM EDT - 8 months ago

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

Jul 9, 2025, 8:00 AM EDT - 9 months ago

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

KALA BIO to Present at Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 10 months ago

KALA BIO to Present at Jefferies Global Healthcare Conference

KALA BIO Announces Chief Executive Officer Transition

Feb 12, 2025, 8:00 AM EST - 1 year ago

KALA BIO Announces Chief Executive Officer Transition

KALA BIO Announces $10,750,000 Private Placement

Dec 30, 2024, 8:00 AM EST - 1 year ago

KALA BIO Announces $10,750,000 Private Placement

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 14, 2024, 4:05 PM EDT - 2 years ago

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

Feb 26, 2024, 8:00 AM EST - 2 years ago

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 19, 2024, 4:01 PM EST - 2 years ago

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 8:00 AM EST - 2 years ago

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 8:00 AM EDT - 2 years ago

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 4, 2023, 8:00 AM EDT - 2 years ago

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

KALA BIO to Participate in Upcoming Investor Conferences in August

Aug 2, 2023, 4:01 PM EDT - 2 years ago

KALA BIO to Participate in Upcoming Investor Conferences in August

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 19, 2023, 4:01 PM EDT - 2 years ago

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

Jun 2, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Mar 27, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 8, 2023, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 3, 2023, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Dec 30, 2022, 12:02 PM EST - 3 years ago

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Dec 29, 2022, 8:30 AM EST - 3 years ago

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Dec 28, 2022, 6:48 AM EST - 3 years ago

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Dec 27, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Nov 28, 2022, 4:02 PM EST - 3 years ago

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Nov 28, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 8, 2022, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Nov 1, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Kala Pharmaceuticals Announces Reverse Stock Split

Oct 20, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Reverse Stock Split

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 19, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Aug 18, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 11, 2022, 7:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Aug 4, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Jul 11, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

Jun 2, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

Why Kala Pharmaceuticals Shares Are Rising Today

May 23, 2022, 10:17 AM EDT - 4 years ago

Why Kala Pharmaceuticals Shares Are Rising Today

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

May 23, 2022, 12:01 AM EDT - 4 years ago

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 16, 2022, 7:00 AM EDT - 4 years ago

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

Atif98
Atif98 Mar. 21 at 6:01 PM
$KALA
0 · Reply
We_the_People_Fight
We_the_People_Fight Mar. 21 at 2:47 AM
$KALA So the AI news for 14-day window lands around: March 26, 2026 Now notice something important… March 26 = Earnings release day That is very interesting timing. Companies often: Release earnings Release PR/news same week Talk about partnership on earnings call Follow earnings with PR announcement This timing actually lines up very Logically: AI filing ~2 weeks later Earnings Earnings call Possible partnership/news
0 · Reply
JustDoItMF
JustDoItMF Mar. 21 at 12:22 AM
$KALA perfect attitude
0 · Reply
Wolfomw02
Wolfomw02 Mar. 20 at 11:03 PM
$KALA have a great weekend everybody! Do something fun get out of the house... Try to forget about the stock for now, come back with renewed interest. Because you all know news is coming next week. And we know what's going to be good because there's already been a buyer.. I guarantee there will be several more! Especially when they tell us what it actually does and how it performs on the 25th... Don't fret, we are either at the bottom or close to it. I'm used to the negative loss already I've been in this for quite a while. But I believe this is something special! and a sign of growth! Please be patient good things will come! But if you can't be patient, please get out and come back because we do need you!! I have 31,500 shares, scaled down from .44 to .32. I'm in it to win it! You should be too!
1 · Reply
We_the_People_Fight
We_the_People_Fight Mar. 20 at 10:27 PM
$KALA
0 · Reply
Momikhan
Momikhan Mar. 20 at 10:16 PM
$KALA so here is my summary for this stock at the moment. Positives AI Product Shipment Clearance of Partial Debt Working with other clients Oversold (Chance of Dead Cat bounce) High CTB Probably sold out to big company if product os good then it will go to Black swan or moon Shot event. Negatives Initial Drug or product failed Zero Revenue Nasdaq delisting notice tickling Continuous Decline with no active buyers Dilution Low cash. Important events 25th March for shipped product update 30th March Financial release (Investors will look cash burn details) My advice. Don't buy or sell at least till 30th of March yes you can average down but it's extreme risky, this is do and die stock. Invest on your own research. Thanks Goodnight !
1 · Reply
JustDoItMF
JustDoItMF Mar. 20 at 9:39 PM
$KALA for fun lets say you're right they would cancel it after the ridiculous pump and many wont even be here
0 · Reply
JustDoItMF
JustDoItMF Mar. 20 at 9:35 PM
$KALA Dont be so life and death the market was down and this company is sun in your eyes bright
1 · Reply
bilocelhi
bilocelhi Mar. 20 at 9:34 PM
$KALA RS within next three weeks. Mark it
0 · Reply
FinacialSuicide
FinacialSuicide Mar. 20 at 9:02 PM
$KALA very disappointing week! Holding next week as well! Hopefully that shipping news comes before the 25th. Let wait and see for now!
1 · Reply
NorthernMonkey1
NorthernMonkey1 Mar. 20 at 7:49 PM
$KALA / $BIAF / $CXAI Do or die hold for the weekend All or nothing! 🫡
0 · Reply
BlazingStocks
BlazingStocks Mar. 20 at 5:36 PM
$KALA - AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry https://finance.yahoo.com/news/red-light-holland-engages-kala-121500405.html
0 · Reply
Germinator3001
Germinator3001 Mar. 20 at 5:23 PM
$KALA Monday😪, Tuesday😔 aaaannnnddddd Wednesday 😊💵🤗💵🤗💵🤗💵🤗💵
0 · Reply
Momikhan
Momikhan Mar. 20 at 5:20 PM
$KALA reversal starts guys
0 · Reply
Momikhan
Momikhan Mar. 20 at 4:54 PM
$KALA panic starts once it Reverses today as Mknday till Wednesday are most important for this stock. Get ready for Do or die situations. Dear Lord Help us.
0 · Reply
Mixupp
Mixupp Mar. 20 at 4:50 PM
$KALA
0 · Reply
We_the_People_Fight
We_the_People_Fight Mar. 20 at 4:38 PM
$KALA fly boy
1 · Reply
Kush957
Kush957 Mar. 20 at 4:37 PM
$KALA
0 · Reply
IChiGOdoranZ
IChiGOdoranZ Mar. 20 at 4:25 PM
$KALA News : Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate https://finance.yahoo.com/news/red-light-holland-engages-kala-130000125.html
0 · Reply
SmallCapGrowth
SmallCapGrowth Mar. 20 at 4:23 PM
$KALA - Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate https://www.tiktok.com/@stocksonhighalert713/video/7618578228566887701 @frontpagestocks
0 · Reply
We_the_People_Fight
We_the_People_Fight Mar. 20 at 4:04 PM
$KALA Definitely trending general market. Companies are reserved with good news untill markets are green in most cases. By 1PM we see shift sideways then 3 pm we see spike to 24 cents. Basically, repeat behavior
1 · Reply
Momikhan
Momikhan Mar. 20 at 3:59 PM
$KALA if it closes at 25 cents then get ready for moon shot if it closes at around 22.50 cents probably it will sink more.
0 · Reply